Esperion Therapeutics
ESPR
$1.90
Share price
-4.52%
Change (1 day)
52.00%
Change (1 year)
Categories
Esperion Therapeutics (ESPR) - Cash on Hand
Cash on Hand as of December 2023 : $82.24 M
According to Esperion Therapeutics's latest financial reports the company has $82.24 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Esperion Therapeutics - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $82.24 M | -50.71% |
| 2022-12-31 | $0.16 B | -35.66% |
| 2021-12-31 | $0.25 B | -14.96% |
| 2020-12-31 | $0.30 B | 51.89% |
| 2019-12-31 | $0.20 B | 47.61% |
| 2018-12-31 | $0.13 B | -32.06% |
| 2017-12-31 | $0.20 B | -5.38% |
| 2016-12-31 | $0.21 B | -0.32% |
| 2015-12-31 | $0.21 B | 100.55% |
| 2014-12-31 | $0.10 B | 76.22% |
| 2013-12-31 | $60.06 M | 822.4% |
| 2012-12-31 | $6.51 M | 314.46% |
| 2011-12-31 | $1.57 M | |
| 2002-12-31 | $44.85 M | -36.19% |
| 2001-12-31 | $70.28 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $12.69 B | 15,328.95% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | $10.84 B | 13,085.49% | 🇺🇸 USA |
 Ultragenyx RARE | $0.57 B | 601.79% | 🇺🇸 USA |
 Lexicon Pharmaceuticals
LXRX | $0.21 B | 165.57% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | $0.28 B | 247.97% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.07 B | 1,205.58% | 🇺🇸 USA |